Couverture de Oncology podcast on PDT (Dr Nazar Vasyliv)

Oncology podcast on PDT (Dr Nazar Vasyliv)

Oncology podcast on PDT (Dr Nazar Vasyliv)

De : Andrew Campbell
Écouter gratuitement

À propos de cette écoute

His study significantly shapes our understanding of glioblastoma treatment by introducing an innovative approach that combines photodynamic therapy (PDT) with necroptosis induction. By targeting glioblastoma stem cells—those most resistant to conventional therapies—this method offers new possibilities for more precise surgical outcomes, reduced recurrence, and the development of personalised treatment strategies. Findings demonstrate that inducing necroptosis, a regulated form of cell death, following PDT could bring about notable clinical benefits, particularly by addressing glioblastoma’s well-known resistance to apoptosis. This marks an important advancement in tackling the complexities of glioblastoma treatment, with the potential to improve therapeutic outcomes and extend survival rates for patients facing this aggressive brain tumour.

dx.doi.org/10.13140/RG.2.2.28609.98400

 Hygiène et vie saine Maladie et pathologies physiques Science
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • Oncology research (led by Dr Nazar Vasyliv)

      Oncology research (led by Dr Nazar Vasyliv)
      Feb 12 2025

      His study significantly shapes our understanding of glioblastoma treatment by introducing an innovative approach that combines photodynamic therapy (PDT) with necroptosis induction. By targeting glioblastoma stem cells—those most resistant to conventional therapies—this method offers new possibilities for more precise surgical outcomes, reduced recurrence, and the development of personalised treatment strategies. Findings demonstrate that inducing necroptosis, a regulated form of cell death, following PDT could bring about notable clinical benefits, particularly by addressing glioblastoma’s well-known resistance to apoptosis. This marks an important advancement in tackling the complexities of glioblastoma treatment, with the potential to improve therapeutic outcomes and extend survival rates for patients facing this aggressive brain tumour.

      dx.doi.org/10.13140/RG.2.2.28609.98400
      Afficher plus Afficher moins
      15 min
    Aucun commentaire pour le moment